In the present work, we show that long-term oral administration of the dual FXR/ membrane G protein-coupled receptor (TGR5) agonist INT-767 prevents HCC formation in Abcb4−/− and not in Fxr−/− mice. This evidence concerns the gene ABCB4 and hepatocellular carcinoma.